A little-known biotech firm focused on Traditional Chinese Medicine has surged over 64,000%, catapulting its valuation to nearly $10 billion. Is this a biotech breakthrough, a speculative frenzy, or something in between?
Join Dan Koh and Ryan Huang as they dissect the rise of Regencell Bioscience Holdings Limited — a company with just 12 employees, no FDA-approved products, and a CEO earning $1 a year.

Bigger Pic: From Building Maintenance to Space Tech
07:32

Mind Your Business: How Abel Richard went from managing power plants to selling 6 figure handbags
13:26

Morning Shot: Singaporeans Caught in the Middle East Conflict - The Race to Get Home
09:04